Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.
Journal: Diabetes, obesity & metabolism
Published: May 16, 2025
LY3522348, A New Ketohexokinase Inhibitor: A First-in-Human Study in Healthy Adults.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: March 05, 2025
Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: December 13, 2023
GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply.
Journal: The New England journal of medicine
Published: December 13, 2023
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
Journal: Lancet (London, England)
Published: June 27, 2023
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
Journal: The New England journal of medicine
Published: June 23, 2023
Practical Applications of a Nausea and Vomiting Model in the Clinical Development of Additional Doses of Dulaglutide.
Journal: Journal of clinical pharmacology
Published: April 10, 2023
General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trial.
Journal: Cardiovascular diabetology
Published: November 28, 2022
Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: June 26, 2022
Examining the evidence for weight management in individuals with type 2 diabetes.
Journal: Diabetes, obesity & metabolism
Published: January 26, 2022
A model-based simulation of glycaemic control and body weight when switching from semaglutide to 3.0- and 4.5-mg doses of once-weekly dulaglutide.
Journal: Diabetes, obesity & metabolism
Published: July 22, 2021
Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.
Journal: Cardiovascular diabetology
Published: July 12, 2021
Last Updated: 09/26/2026